Summary & Overview
HCPCS Q5150: Aflibercept-mrbb (Ahzantive) Injection, 1 mg
HCPCS Level II code Q5150 identifies the 1 mg injection of aflibercept-mrbb (Ahzantive), a biosimilar used for intravitreal anti-VEGF therapy. This code matters nationally as biosimilar ophthalmic biologics enter clinical practice and payer formularies, influencing drug access, cost management, and benefit design for retinal disease treatment. The code enables standardized reporting of this specific biosimilar product separate from its reference biologic.
Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise synthesis of what the code represents, the typical clinical setting for administration, and the payer landscape covered. The publication provides benchmarks and coverage context where available, summarizes relevant policy and coding guidance affecting biosimilar injections, and outlines clinical context for intravitreal aflibercept use.
This summary is intended for billing managers, revenue cycle professionals, and clinical administrators who need a national-level overview of the code, how it maps to service delivery, and what topics to consider when integrating the biosimilar into practice workflows and payor interactions. Data not available in the input is indicated where applicable.
Billing Code Overview
HCPCS Level II code Q5150 describes an injection of aflibercept-mrbb (Ahzantive), biosimilar, 1 mg. This service is a biologic medication administration for ocular conditions that require intravitreal anti-VEGF therapy. The service type is medication injection/biologic administration, typically delivered as an intravitreal injection. The typical site of service is an outpatient ophthalmology clinic or ambulatory surgery center where intravitreal injections are performed.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with neovascular (wet) age-related macular degeneration or macular edema due to retinal vein occlusion or diabetic macular edema who presents to an ophthalmology clinic for an intravitreal anti-VEGF injection. The medication administered is aflibercept-mrbb (Q5150, 1 mg), a biosimilar to aflibercept. Clinical workflow: patient arrival and registration, verification of medication and informed consent, vision and intraocular pressure check, topical anesthesia and antisepsis, sterile drape and eyelid speculum placement, measured intravitreal injection of Q5150 into the vitreous cavity, post-injection assessment including intraocular pressure and brief observation for adverse events, documentation of lot number and expiration, and scheduling of follow-up visits or further injections as indicated. Typical site of service is an ambulatory ophthalmology clinic, procedure room, or hospital outpatient department where intravitreal injections are routinely performed. Common patient modifiers that may apply include medical necessity or bilateral procedures, anesthesia circumstances, or organizational payment reporting modifiers as indicated by payer policies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services | Use when work or complexity for the injection is substantially greater than typical (rare for standard intravitreal injection; document specifics). |